ADAR1 Capital Management’s Neurogene NGNE Stock Holding History

ADAR1 Capital Management’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$245K	Buy	+7,800	New	+$215K	0.01%	244
2026 Q1	–	Sell	-30,633	Closed	-$631K	–	328
2025 Q4	$631K	Hold	30,633	–	–	0.05%	174
2025 Q3	$531K	Buy	30,633 +1,008	+3%	+$20.2K	0.05%	132
2025 Q2	$443K	Buy	29,625 +1,700	+6%	+$26.7K	0.07%	123
2025 Q1	$327K	Buy	+27,925	New	+$485K	0.06%	124
2024 Q4	–	Sell	-553	Closed	-$23.2K	–	275
2024 Q3	$23.2K	Sell	553 -700	-56%	-$27.1K	﹤0.01%	241
2024 Q2	$45.6K	Buy	1,253 +592	+90%	+$20.9K	0.01%	190
2024 Q1	$33.6K	Sell	661 -4,744	-88%	-$158K	0.01%	202
2023 Q4	$105K	Buy	+5,405	New	+$77.4K	0.04%	94

Other funds holding NGNE

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

ADAR1 Capital Management's NGNE Position: Q2 2026 in Review

ADAR1 Capital Management opened a new position in Neurogene (NGNE) in Q2 2026: 7,800 shares worth $245K. The stake represents 0.01% of the portfolio and ranks #244 among its holdings. This is a return to the name: ADAR1 Capital Management previously reported a position in NGNE as recently as Q4 2025.

ADAR1 Capital Management first reported a position in NGNE in Q4 2023 and has held it in 9 quarters since. The position peaked at $631K in Q4 2025. 112 funds tracked by Wall St. Rank hold NGNE as of Q2 2026.

ADAR1 Capital Management held 7,800 shares of Neurogene worth $245K as of Q2 2026.
Neurogene was a new ADAR1 Capital Management position in Q2 2026.
Neurogene made up 0.01% of ADAR1 Capital Management's portfolio in Q2 2026, its #244 holding.
ADAR1 Capital Management first reported a position in Neurogene in Q4 2023 and has held it in 9 quarters since.
ADAR1 Capital Management's Neurogene position peaked at $631K in Q4 2025.
112 funds tracked by Wall St. Rank held Neurogene as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.